Download PDF
Arzneimittelforschung 2011; 61(7): 373-378
DOI: 10.1055/s-0031-1296213
CNS-active Drugs · Hypnotics · Psychotropics · Sedatives
Editio Cantor Verlag Aulendorf (Germany)

Synthesis and pharmacological evaluation of some quinoline derivatives as potential cognition enhancers

Poonam Piplani
1   University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
,
Anita Rani
1   University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
,
Ruchika Saihgal
1   University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
,
Meenakshi Sharma
1   University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2011 (online)

    Permissions and Reprints

Abstract

The present paper describes the synthesis of a series of substituted 6-amino (1 a–c) and 8-aminoquinoline derivatives (2b–c) and the evaluation of their ability to prevent the memory decline using a behavioural model, i. e. the elevated plus maze test. The effect of the candidate drugs on the activity of acetylcholinesterase was studied using the enzyme source from the mouse brain. The structures of the synthesized compounds were confirmed by UV, IR, 1H-NMR and elemental analysis. The 6-aminoquinoline derivative [6-(4-pyridyl)methylaminoquinoline] (1 c) oxalate showed maximum % retention (50% at 5 mg/kg and 75% at 10 mg/kg) in the elevated plus maze test and maximum% inhibition (71% at 25 µM) of AChE on biochemical evaluation.

Key words

Acetycholinesterase - 6-Aminoquinolines - 8-Aminoquinolines - Cogniton enhancers - Elevated plus maze - Quinolines
 

  • References

  • 1 Marta M, Castellano C, Oliverio A, Pavone F, Pagella PG, Brufani M et al. New analogues of physostigmine: alternative drugs for Alzheimer’s disease?. Life Sci. 1988; 43: 1921-8
    CrossrefPubMedGoogle Scholar
  • 2 Gualtieri F. Cholinergic receptors and neurodegenerative diseases. Pharm Acta Helv. 2000; 74: 85-9
    CrossrefPubMedGoogle Scholar
  • 3 Benzi G, Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease?. Eur J Pharmacol. 1998; 346: 1-13
    CrossrefPubMedGoogle Scholar
  • 4 Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986; 315: 1241-5
    CrossrefPubMedGoogle Scholar
  • 5 Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis for geriatric memory disfunction. Science 1982; 217: 408-14
    CrossrefPubMedGoogle Scholar
  • 6 Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem. 1983; 40: 503-9
    CrossrefPubMedGoogle Scholar
  • 7 Gottfries CG. Pharmacological treatment strategies in Alzheimer’s type dementia. Psychopharmacology 1985; 86: 245-4
    CrossrefPubMedGoogle Scholar
  • 8 Perry EK. The cholinergic hypothesis-ten years on. Br Med Bull. 1986; 40: 503-9
    PubMedGoogle Scholar
  • 9 Barril X, Kalko SG, Orozco M, Luque FJ. Rational design of reversible acetylcholinesterase inhibitors. Mini Rev Med Chem. 2002; 2: 27-36
    CrossrefPubMedGoogle Scholar
  • 10 Recanatini M, Cavalli A, Belluti F, Piazzi L, Rampa A, Bisi A et al. SAR of 9-amino-l,2,3,4-tetrahydroacridine based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR and structure-based COMFA of tacrine analogues. J Med Chem. 2000; 43: 2007-18
    CrossrefPubMedGoogle Scholar
  • 11 Camps P, Achab RE, Morral J, Munoz-Torrero D, Badia A, Banos JE et al. New tacrine-hyperzine A hybrids (huprines): Highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer’s disease. J Med Chem. 2000; 43: 4657-66
    CrossrefPubMedGoogle Scholar
  • 12 Camps P, Achab RE, Gorbig DM, Morral J, Munoz-Tarrero D, Badia A et al. Synthesis in vitro pharmacology and molecular modeling of very potent tacrine-hyperzine A hybrids as acetylcholinesterase inhibitors of Alzheimer’s disease. J Med Chem. 1999; 42: 3227-42
    CrossrefPubMedGoogle Scholar
  • 13 Suzuki T, Usui T, Oka M, Suzuki T, Kataoka T. Synthesis and muscarinic activity of a series of quinolines and naphthalenes with a l-azabicyclo[3.3.0]octane moiety. Chem Pharm Bull. 1998; 46: 1265-73
    CrossrefPubMedGoogle Scholar
  • 14 Piplani P, Rani A, Sandhir R, Kulkarni SK. Synthesis and pharmacological evaluation of some quinoline derivatives as potential antiamnesic agents. J Young Pharmacists. 2009; 1: 341-50
    CrossrefPubMedGoogle Scholar
  • 15 Vetulani J, Battaglia M, Sansone M. Nimodipine on shuttle box avoidance Learning in mice: no improvement but slight impairment. Pharmacol Biochem Behav. 1996; 56: 577-81
    PubMedGoogle Scholar
  • 16 Halama A, Kavalek J, Machacek V, Weidlich T. Aromatic nucleophilic subsititution of hydrogen: Mechanism of reaction of 6-nitroquinoline with cyanide ions, with and without participation of methyl cyanoacetate. J Chem Soc Perkin Trans. 1999; 1: 1839-45
    PubMedGoogle Scholar
  • 17 Sharma AC, Kulkarni SK. Evaluation of learning and memory mechanisms employing elevated plus maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiat. 1992; 16: 117-25
    CrossrefPubMedGoogle Scholar
  • 18 Ellman GL, Courtney KD, Andress V, Featherston RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961; 7: 88-95
    CrossrefPubMedGoogle Scholar
  • 19 Lowry OH, Rosenberg NJ, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951; 193: 265-2
    PubMedGoogle Scholar
  • 20 Baker RH, Albisetti CJ, Dodson RM, Lappin GR, Riegel B. The synthesis of some 8-aminoquinolines. J Am Chem Soc. 1946; 68: 1532-6
    CrossrefPubMedGoogle Scholar
  • 21 Furniss BS, Hannaford AJ, Smith PWG, Tatchell AR. Vogel’s textbook of practical organic chemistry. 5th ed. New York: John Wiley & Sons; 1989. p. 890-92
    Google Scholar